The ripple effects of President Donald Trump’s second-term policies continue to unsettle public health agencies nationwide. While the country is still grappling with the aftermath of the COVID-19 pandemic, health officials say recent federal funding cuts are threatening the very infrastructure designed to protect Americans from future crises.

What began as reductions at the federal level has extended to state and local health departments. Roughly $12 billion in federal health funding has been earmarked for elimination, although some of these cuts are on temporary hold due to legal challenges. Local officials warn that even the threat of funding withdrawals is enough to destabilize long-term public health efforts.

Chicago’s Cook County Health Feels the Impact

One of the largest public health systems in the U.S., Cook County Health in Chicago, is already feeling the strain. Dr. Erik Mikaitis, CEO of the system, told the US News that two major grants totaling $31 million were abruptly pulled in March. Although the grants were scheduled to end in a few months, the early termination forced the system to speed up its transition plans.

“We were already in a planning stage,” said Mikaitis, “but we just had to accelerate that a little bit.” He noted that while they expect to retain all employees funded through the grants, outreach efforts have taken a hit. The programs, largely aimed at infectious disease prevention and health literacy, are now scaled back.

Shrinking Resources, Growing Needs

Mikaitis stressed that federal support underpins a broad range of public health functions—from vaccinations and infectious disease control to food and water safety. The withdrawal of funding creates downstream effects across the health system.

“Without public health being robust and able to intervene, we run the risk of having a sicker population,” he said. Smaller clinical sites, already stretched thin, may face closures under the added burden. “And when you reflect that against federal discussions on Medicaid cuts, that creates almost a double impact.”

Bracing for Deeper Cuts

Faced with uncertainty, Cook County Health is preparing for worst-case scenarios. “We’ve taken the tack of really looking at efficiencies—how do we gain revenues before we even look at trying to cut anything,” said Mikaitis. Still, there is concern that deeper cuts, particularly in Medicaid reimbursements, could force reductions in services.

Grants currently fund about a third of the Cook County Department of Public Health’s budget. As those funds disappear, essential functions such as infectious disease surveillance may be at risk.

Long-Term Prevention at Risk

Mikaitis pointed to another looming threat: the potential collapse of preventive care and chronic disease management. Cook County is exploring internal synergies—such as integrating the health plan with public health operations—to cushion the blow.

But he warned that if Medicaid cuts proceed and more people lose coverage, fewer will seek preventive care. “Are we going to be focusing on controlling high blood pressure,” he asked, “or treating strokes and heart attacks?”

For many health officials like Mikaitis, the choice between prevention and crisis response is no choice at all—it’s a compromise no community can afford to make.

In a significant shift, U.S. health authorities have updated their guidance on measles vaccination for international travelers. The Centers for Disease Control and Prevention (CDC) now recommends that all Americans traveling abroad receive the measles-mumps-rubella (MMR) vaccine, regardless of the destination.

Previously, the CDC emphasized the need for vaccination only when traveling to countries with active measles outbreaks. The updated guidance reflects a broader concern: the risk of exposure isn’t limited to countries battling large outbreaks but is also present during international transit, including flights and airports.

Why the Updated Guidance Matters

Ashley Darcy-Mahoney, a professor and researcher at George Washington University’s School of Nursing, described the CDC’s new stance as “significant.” She pointed to a recent outbreak in Colorado that stemmed from an international flight landing in Denver.

“We're seeing a shift from localized outbreaks to transmission in transit,” she explained, adding that the CDC appears to be responding to the growing evidence that travelers can become infected while en route, not just at their destination.

Vaccine Guidance: Who Needs What

The CDC now advises two doses of the MMR vaccine for all Americans aged 1 and older before traveling internationally. Infants aged 6 to 11 months should receive one early dose prior to travel, even though that shot will not count toward the regular two-dose schedule.

Measles is a highly contagious, airborne virus, capable of infecting 90% of unvaccinated individuals who are exposed. Symptoms typically appear 7 to 14 days after exposure and include high fever, cough, runny nose, and a characteristic red rash.

Cases on the Rise Across the U.S.

As of May 30, the U.S. had reported 1,088 measles cases in 2025. Texas remains the epicenter, with 738 confirmed cases, including 10 new cases reported just last week. The outbreak began in late winter and has continued into spring.

Colorado has confirmed seven measles cases so far this year, including an outbreak of three related cases. All three were linked to a mid-May international flight into Denver. The cases involved an unvaccinated child under age 5, a vaccinated adult, and a contagious out-of-state traveler.

Deaths and Widespread Outbreaks

Tragically, three measles-related deaths have been reported during this year’s outbreak: two young children from Texas and one adult in New Mexico, all of whom were unvaccinated.

Currently, the CDC has identified active outbreaks in 11 states, including Colorado, Kansas, Michigan, Montana, New Mexico, North Dakota, Ohio, Oklahoma, Pennsylvania, Tennessee, and Texas. Measles cases have also been reported in more than 30 other states, from California and Florida to New York and Washington.

Vaccine Rates Falling Below Target

Though measles was declared eliminated from the U.S. in 2000, vaccination coverage has dropped. A November report by health policy think tank KFF noted that only 11 states met the CDC’s 95% vaccine coverage goal for kindergarteners in the 2023–24 school year, compared to 22 states in 2019–20.

Health Officials Urge Immunization

Despite past skepticism about vaccines, Health and Human Services Secretary Robert F. Kennedy Jr. recently acknowledged on social media that “the most effective way to prevent the spread of measles is the MMR vaccine.” However, he also called for a review of the childhood vaccine schedule, citing concerns about links to chronic diseases—a stance that has sparked fresh controversy.

As measles cases continue to rise, public health experts stress that vaccination remains the most effective way to protect individuals and prevent further spread.

Cancer therapy is ever-evolving with new tests, treatments and pills- and in the middle of it is a revolutionary technology known as liquid biopsy. Just to think of a simple blood test that can diagnose cancer in its early stages, predict how a tumor will respond to treatment, and help doctors to change medications before cancer has a chance to develop anew. That's no longer science fiction anymore. Liquid biopsy is transforming the way we detect and treat cancer giving new hope to patients and changing the face of oncology.

Unlike earlier biopsies, in which tissue has to be taken from the tumor itself—usually through surgery or needle biopsies—a liquid biopsy is as easy as a blood test. This blood is then tested for circulating tumor DNA (ctDNA) or shed tumor cells in the blood. These bits contain the genetic material of the tumor and enable physicians to learn about the molecular nature of the cancer without gaining direct access to the tumor.

The latest versions of this test can even identify small, sinister changes in proteins—providing important clues about what a tumor might do and whether it is developing resistance to therapy.

A recent study published in The New England Journal of Medicine which was presented at the American Society of Clinical Oncology annual meeting illustrates just how potent liquid biopsy can be. The study involved individuals with estrogen-fueled metastatic breast cancer—a sub-type that is generally treated with medications that attack specific proteins on cancer cells.

With time, tumors evolve and these mutations can make treatments ineffective. In the research, scientists employed liquid biopsies to identify such protein mutations as far back as nine months prior to when they could be seen on conventional imaging scans. Early detection enabled doctors to change treatments preemptively—radically enhancing outcomes.

We have highly effective treatments, but they have to wear off," said Dr. Nicholas Turner, the study's co-author and a professor of molecular oncology at The Royal Marsden Hospital. "If we can pick up the changes early, we can move quickly—before the cancer does any more damage."

How Liquid Biopsies Could Enhance Outcomes?

The research had 315 patients, all of whom had acquired mutations following treatment. The liquid biopsy findings influenced a change in treatment in half of the cohort, with the other half retaining treatment as before.

Patients who had changed their treatment were twice as likely to maintain their tumors at bay in the coming year. Liquid biopsies could identify mutations up to nine months before conventional scans. In 10% of the volunteers, the test showed their treatment was no longer working, before symptoms or scans could detect it.

These results indicate a significant change in the way we monitor cancer and make medication changes—equipping clinicians and patients with sooner insights and more tailored treatment alternatives.

While this most recent study focused on breast cancer, liquid biopsy is being designed for a broad spectrum of cancers. A case in point is lung cancer, where liquid biopsies are already producing results 16 days sooner than traditional tissue biopsies, based on pilot data from the UK's National Health Service (NHS).

This quicker turnaround enables patients to initiate life-extending, targeted treatments sooner—potentially avoiding the lag that allows cancer to develop further.

NHS National Clinical Director for Cancer, Professor Peter Johnson, captured the potential of liquid biopsies perfectly:

"They are taking us into a new age of personalized cancer treatment… and we can see the difference this test is already making."

In 2022, Australian scientists reported in The New England Journal of Medicine that liquid biopsy could predict whether individuals with early-stage colon cancer required chemotherapy following surgery. This enabled numerous patients to safely avoid chemotherapy, sparing them its energy-sapping side effects without sacrificing for treatment effectiveness.

Dr. Jeanne Tie, senior research fellow at the Walter and Eliza Hall Institute of Medical Research in Australia and lead author of the study, underlined that liquid biopsies could soon become routine tools in early cancer treatment and management, but availability still differs around the world.

How Does Liquid Biopsy Work?

The secret of this groundbreaking test is its capacity for analyzing ctDNA, or pieces of tumor DNA circulating in the bloodstream. These pieces provide a molecular snapshot of the tumor, exposing important genetic mutations that reveal:

• How aggressive the cancer is
• Whether it's responding to current treatment
• Which treatments are most likely to be effective

By detecting these changes earlier, liquid biopsies allow physicians to match patients with targeted treatments—drugs that are customized to a tumor's own individual genetic signature. Chief Scientific Officer for England Professor Dame Sue Hill welcomed this technology, "This technology is revolutionizing care and enabling clinicians to match patients sooner with potentially life-prolonging targeted therapies."

Liquid biopsy is not only a more accurate or quicker test—it's also cheaper and less invasive. One independent health economics review in the UK estimated that liquid biopsies would save the NHS as much as £11 million annually in lung cancer treatment alone.

Moreover, by minimizing the necessity for repeat scans, invasive biopsies, or cycles of unwanted chemotherapy, the test is also improving quality of life for many patients.

As the technology becomes even more advanced, researchers are looking to utilize it for:

• Pancreatic and gallbladder cancer
• Monitoring cancer growth and treatment response in real-time
• Screening healthy people for early cancer signs—before symptoms even begin

Cancer patients as well as patients with conditions such as cystic fibrosis and chronic pancreatitis are now confronted with an acute shortage of an essential medication—Creon. This pancreatic enzyme replacement therapy (PERT) is crucial to digesting food, one of the most fundamental of human activities which becomes all but impossible for those with pancreatic insufficiency.

The consequences are frightening- patients are forgoing meals, dividing up doses, and driving more than 30 miles just to receive the capsules. The effect is not just nutritional but life-threatening, because not being able to properly digest food can make a person vulnerable to infection, make them weaker, and restrict access to life-saving treatment like chemotherapy.

Creon is the brand name of pancreatic enzyme replacement therapy that is used to manage exocrine pancreatic insufficiency (EPI)—a disease in which the pancreas is unable to produce enzymes to help digest food. This inability can be due to a variety of reasons, such as pancreatic cancer, cystic fibrosis, chronic pancreatitis, and complications after surgery like gastric-bypass or pancreatic surgery.

For individuals with EPI, Creon® is not merely a supportive therapy—it is a lifeline. It allows them to extract nutrition from food and sustain body weight, energy, and immune capacity. Without it, patients experience persistent diarrhea, abdominal pain, malnutrition, and ultimately, reduced quality of life and survivability.

The Government in the UK has prolonged the Serious Shortage Protocol (SSP) for Creon until November 2025, enabling pharmacists to dispense a reduced quantity without a fresh prescription. Although the policy tries to make things more accessible, this is a short-term solution to an ongoing and hazardous shortage.

One survey carried out by the National Pharmacy Association (NPA), surveying more than 300 pharmacies, shows a dire picture. A whopping 96% of these pharmacies are struggling to get Creon, the essential pancreatic enzyme replacement therapy. Additionally, 89% have the same shortages with other drugs like Nutrizym and Pancrex. This shortage is making many patients go distances of over 30 miles just to get a pharmacy that will fill their prescriptions. Even more alarming, many patients are said to be skipping meals or cutting their doses in order to stretch their short supplies, jeopardizing their health and wellbeing in the process.

The shortage is primarily due to "European-wide supply issues" and production limitations on the drug that have caused interruptions in the manufacture and distribution of Creon, as reported by the Department of Health and Social Care. The interruptions are not specific to Creon but point to systemic weaknesses in pharmaceutical production.

In Creon's case, though, the end result is worse. Unlike certain drugs that can be skipped or substituted for others, Creon® is instantly vital with each patient meal. There is no "respite" from taking it, and even temporary discontinuation can cause health emergencies.

How is the Shortage of the Drug Affecting Cancer Patients?

The psychological and physical strain on the patients cannot be estimated. As Alfie Bailey-Bearfield, Pancreatic Cancer UK's Head of Influencing & Health Improvement, stressed, "It's completely unacceptable that they are still taking desperate steps which risk their health, wellbeing, and their suitability for treatment."

Patients going without meals in order to cut corners on enzyme capsules put themselves at significant risk of malnutrition and severe weight loss. Not only does this compromise the immune response of the body, it lowers tolerance to chemotherapy, effectively excluding patients from life-sustaining or curative therapy. The medical risk is not abstract—it's real and measurable.

What is EPI?

Exocrine Pancreatic Insufficiency (EPI) is more prevalent than many people know. In the UK alone, approximately 61,000 patients need pancreatic enzyme therapy. Reasons are:

• Pancreatic cancer (especially advanced)
• Cystic fibrosis
• Chronic and acute pancreatitis
• Pancreatic surgery or gastric bypass
• Untreated celiac disease or inflammatory bowel disease

EPI results in undigested food entering the colon, leading to bloating, gas, cramps, and diarrhea. With time, the nutrient deficiencies cause weight loss, bone loss, and even increased cardiovascular risk. In children, it impairs growth and development.

Unlike regular prescriptions, Creon is not prescribed with a set amount. It has to be individualized for each patient, for each meal, and even for each snack. The dosing is 3,000 to 36,000 enzyme units per capsule. For comparison, a normal pancreas will release up to 720,000 units for a small meal.

Patients are instructed to self-regulate according to their intake, so that a consistent and plentiful source becomes not only the preferred but also the necessary mode of correct dosing. Under shortages, this individualized dosing is a luxury many cannot enjoy.

Healthcare providers and patient advocacy groups alike are demanding immediate government action. Bailey-Bearfield and Picard have issued public calls for a strategic restructuring to solve manufacturing constraints and enhance distribution systems.

"This crisis continues to put people's health at risk, and they cannot afford to wait any longer," Bailey-Bearfield implored.

It takes not only stockpiling but also long-term planning, such as investment in alternative manufacturing hubs, local production incentives, and better global supply chain coordination.